Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

Dalton Pharma Services and Lonza jointly announce a co-operation created to provide clients with geographically diversified, fully integrated chemistry services from bench to commercial production of active pharmaceutical ingredients.

15 Nov 2010

UAS Laboratories acquires outstanding shares of APN Labs

On November 11, 2010, UAS Laboratories, Inc. acquired all outstanding shares of APN Labs, Inc. to become the sole owner. APN Labs, Inc. of Wausau, Wisconsin, USA, has been a leading contract manufacturer of nutraceuticals for the past 10 years. APN Labs has its own condition-specific probiotic blends as well as other ingredients.

14 Nov 2010

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2010.

12 Nov 2010

Abaxis releases new Piccolo reagent disc panel

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced the release of a new Piccolo® reagent disc panel called BioChemistry Panel Plus. This new reagent disc will be used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

12 Nov 2010

NovaBay third quarter net loss increases to $1.6 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has reported third quarter financial results and highlighted the clinical progress of its in-house programs.

12 Nov 2010

Research output from Asia and Europe surpasses that of the US

A study from Thomson Reuters released today shows that the US is no longer the "colossus of science" that it was and has not kept pace with the increased output from European and Asia-Pacific nations.

12 Nov 2010

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

The New York Times: A civil trial against the drugmaker Merck is now underway in Manhattan. A retired investigator for the U.S. army is one of 1,400 people suing the company on the premise that Fosamax, a Merck drug used by millions of women with thinning bones, caused them to develop jawbone ailments.

12 Nov 2010

Roche, CapitalBio to initiate strategic partnership for molecular diagnostic applications

Roche Diagnostics and CapitalBio have announced their intention to initiate a strategic partnership targeting molecular diagnostic applications and the development of technologies to fill the unmet needs of researchers worldwide. This new development builds on the genomics and diagnostics expertise of the two companies and will focus on furthering microarray technologies and complementary products for molecular diagnostic applications.

From Roche Sequencing and Life Science 11 Nov 2010

NIST develops new Vaccinium berry suite of standard reference materials

National Institute of Standards and Technology (NIST) researchers have developed new certified reference materials for measuring amounts of organic acids in dietary supplements formulated with Vaccinium berries-cranberries, blueberries and bilberries. As described in a recent paper, manufacturers and researchers can use this new suite of standard reference materialsTM (SRMs) as quality assurance tools.

11 Nov 2010

HHS unveils new bolder tobacco control strategy

U.S. Department of Health and Human Services today unveiled a new comprehensive tobacco control strategy that includes proposed new bolder health warnings on cigarette packages and advertisements. Once final, these health warnings on cigarettes and in cigarette advertisements will be the most significant change in more than 25 years. These actions are part of a broader strategy that will help tobacco users quit and prevent children from starting.

11 Nov 2010

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into a single therapy, announced today that a profile of the company and its pipeline is featured in the November 21 issue of BioWorld Today in the NewCo section.

11 Nov 2010

Dendreon requests licensure for additional capacity to manufacture PROVENGE at New Jersey facility

Dendreon Corporation today announced that it has completed the submission of the post-approval supplement to the PROVENGE® (sipuleucel-T) Biologics License Application for the Morris Plains, New Jersey manufacturing facility. Dendreon is requesting licensure for an additional 36 workstations to manufacture PROVENGE. The standard U.S. Food and Drug Administration (FDA) review for a post-approval supplement to a Biologics License Application is typically four months.

11 Nov 2010

Bioniche Life Sciences announces first quarter fiscal 2011 results

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of its 2011 fiscal year (ended September 30, 2010).

10 Nov 2010

Study finds no association between working in wafer fabrication cleanrooms, cancer mortality

An exhaustive, five-year epidemiological study conducted by researchers from Vanderbilt University covering more than 100,000 semiconductor industry workers found no association between overall cancer mortality and working in wafer fabrication cleanrooms, the Semiconductor Industry Association reported today.

10 Nov 2010

Cerus prices underwritten public offering

Cerus Corporation today announced the pricing of an underwritten public offering of 7,368,422 units, with each unit consisting of one share of its common stock and a warrant to purchase 0.5 of a share of its common stock, at a price to the public of $2.85 per unit. The aggregate public offering price of this offering is approximately $21.0 million, and the net proceeds to the Company, after deducting underwriting discounts and commissions, but before legal and other estimated offering expenses, are expected to be approximately $19.7 million.

10 Nov 2010

Genpact to implement process optimization programs for Manipal Health Enterprises

Genpact Limited, a global leader in business process and technology management, today announced a five-year contract with Manipal Health Enterprises Pvt. Limited (MHE), one of the largest tertiary care hospital chains in India. Genpact will implement process optimization programs for MHE's 11 hospitals across India by leveraging its proprietary Smart Enterprise Processes (SEPSM) methodology.

10 Nov 2010

Malaria drug artesunate found more effective than quinine at preventing severe falciparum malaria deaths in children, study says

Researchers found that the death rate among children diagnosed with severe falciparum malaria was almost one-fourth lower when they received the drug artesunate rather than the standard treatment of quinine, according to research which was presented at the American Society for Tropical Medicine and Hygiene (ASTMH) over the weekend and published Monday in the Lancet, HealthDay News/U.S. News and World Report writes.

10 Nov 2010

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has held its second meeting with the Australian Therapeutic Goods Administration ("TGA") to discuss milestones for approval of PV-10 for treatment of metastatic melanoma. The TGA is the part of the Australian Government's Department of Health and Ageing responsible for the assessment, approval and monitoring of therapeutic goods available in Australia. The initial meeting with the TGA was held in October 2008.

9 Nov 2010

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and a financial update for the third quarter ended September 30, 2010.

9 Nov 2010

Manufacturing News and Research

Further Reading

Sinovac third quarter sales decrease 7% to $9.6 million

Dalton Pharma enters co-operation with Lonza to provide integrated chemistry services

UAS Laboratories acquires outstanding shares of APN Labs

Derma Sciences net sales for third quarter 2010 increase 17% to $15,096,134

Abaxis releases new Piccolo reagent disc panel

NovaBay third quarter net loss increases to $1.6 million

Research output from Asia and Europe surpasses that of the US

Drug industry roundup: Fosamax trial focuses scrutiny on osteoporosis drugs; What about $4 generics; Recalls undermining confidence

Roche, CapitalBio to initiate strategic partnership for molecular diagnostic applications

NIST develops new Vaccinium berry suite of standard reference materials

HHS unveils new bolder tobacco control strategy

BioWorld Today features ImmunGene's pipeline of next generation armed antibodies for cancer

Dendreon requests licensure for additional capacity to manufacture PROVENGE at New Jersey facility

Bioniche Life Sciences announces first quarter fiscal 2011 results

Study finds no association between working in wafer fabrication cleanrooms, cancer mortality

Cerus prices underwritten public offering

Genpact to implement process optimization programs for Manipal Health Enterprises

Malaria drug artesunate found more effective than quinine at preventing severe falciparum malaria deaths in children, study says

Provectus holds second meeting with Australian TGA to review approval of PV-10 for metastatic melanoma

Discovery Labs reports net operating loss of $6.2 million for third quarter 2010

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy